Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer by Toshio Ohashi et al.
Ohashi et al. Radiation Oncology 2014, 9:13
http://www.ro-journal.com/content/9/1/13RESEARCH Open AccessCombined brachytherapy and external beam
radiotherapy without adjuvant androgen
deprivation therapy for high-risk prostate cancer
Toshio Ohashi1,2*, Atsunori Yorozu3, Shiro Saito4, Tetsuo Momma5, Toru Nishiyama4, Shoji Yamashita2,
Yutaka Shiraishi1 and Naoyuki Shigematsu1Abstract
Background: To report the outcomes of patients treated with combined iodine-125 (I-125) brachytherapy and
external beam radiotherapy (EBRT) for high-risk prostate cancer.
Methods: Between 2003 and 2009, I-125 permanent prostate brachytherapy plus EBRT was performed for 206
patients with high-risk prostate cancer. High-risk patients had prostate-specific antigen≥ 20 ng/mL, and/or Gleason
score ≥ 8, and/or Stage ≥ T3. One hundred and one patients (49.0%) received neoadjuvant androgen deprivation
therapy (ADT) but none were given adjuvant ADT. Biochemical failure-free survival (BFFS) was determined using the
Phoenix definition.
Results: The 5-year actuarial BFFS rate was 84.8%. The 5-year cause-specific survival and overall survival rates were
98.7% and 97.6%, respectively. There were 8 deaths (3.9%), of which 2 were due to prostate cancer. On multivariate
analysis, positive biopsy core rates and the number of high-risk factors were independent predictors of BFFS. The
5-year BFFS rates for patients in the positive biopsy core rate <50% and ≥50% groups were 89.3% and 78.2%, respectively
(p = 0.03). The 5-year BFFS rate for patients with the any single high-risk factor was 86.1%, compared with 73.6% for those
with any 2 or all 3 high-risk factors (p = 0.03). Neoadjuvant ADT did not impact the 5-year BFFS.
Conclusions: At a median follow-up of 60 months, high-risk prostate cancer patients undergoing combined I-125
brachytherapy and EBRT without adjuvant ADT have a high probability of achieving 5-year BFFS.
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The prognosis for men with clinically localized, high-risk
prostate cancer treated with external beam radiotherapy
(EBRT) has improved significantly over the last 15 years
[1-7]. Most notably, the addition of androgen deprivation
therapy (ADT) to standard dose EBRT has been shown in
several large, randomized studies to increase cause-specific
survival (CSS) and overall survival (OS) [1,2]. In addition,
increasing the external beam dose to 78–80 Gy has led to
improvements in biochemical failure-free survival (BFFS)* Correspondence: ohashi@rad.med.keio.ac.jp
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reproduction in any medium, provided the or[3-6]. However, even with these improvements, high-risk
prostate cancer remains a therapeutic challenge for both
urologists and radiation oncologists.
Stock et al. documented results for a series of patients
with high-risk disease receiving trimodality therapy con-
sisting of brachytherapy, EBRT and ADT, reporting ex-
cellent biochemical and pathologically confirmed local
control [8]. Their group also reported a recent series
showing favorable distant control and disease-specific
survival in men with Gleason score 8–10 disease [9],
and long-term biochemical control in men with extra-
prostatic disease [10]. Brachytherapy provides a means
to further raise the local dose and has been used in an
attempt to improve results in men with high-risk dis-
ease. With high biologic effective doses (BED) being
achievable with EBRT plus brachytherapy, BFFS rates ofLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of men with high-risk disease [11,12]. Some previous
studies demonstrated a benefit of ADT used in conjunc-
tion with EBRT to treat locally advanced prostate cancer
[1,2,13]. However, these studies, which demonstrated an
advantage with the addition of ADT, were conducted
during a period when radiation doses may have been in-
adequate to control all local disease. Clear evidence for
using adjuvant ADT when much higher radiation doses
are delivered is thus lacking.
The use of permanent prostate brachytherapy employ-
ing iodine-125 (I-125) seeds has expanded rapidly in
Japan since the establishment of guidelines for this treat-
ment modality and revision of the dosimetric regulations
related to radiation hazards and safety in 2003. In this
report, we summarize the clinical outcomes of patients
in our experience receiving combined therapy consisting
of permanent prostate brachytherapy and EBRT without
adjuvant ADT.
Methods
Between September 2003 and June 2009, 206 consecutive
Japanese patients with high-risk localized prostate cancer
were treated with combined modality therapy consisting
of I-125 permanent seed implantation and supplemental
EBRT at either the National Hospital Organization Tokyo
Medical Center or the National Hospital Organization
Saitama Hospital. These patients included men with a
prostate-specific antigen (PSA) level higher than 20 ng/mL,
and/or Gleason score ≥ 8, and/or Stage T3. Clinical T
stage was classified by combination of magnetic resonance
imaging finding and digital examination by urologist.
There were no treatment policy discrepancies between the
National Hospital Organization Tokyo Medical Center
and National Hospital Organization Saitama Hospital.
One hundred and one patients (49.0%) received neoadju-
vant ADT with the aim of prostate volume reduction or a
longer waiting time. Regarding the aim of volume reduc-
tion, patients with prostate volumes >40 cc usually under-
went ADT because Japanese national policy for patient
discharge criteria mandates that total seed activity be kept
below 1,300 MBq. None of our present patients received
adjuvant ADT. ADT consisted of luteinizing hormone-
releasing hormone agonist alone or in combination with
an anti-androgen. The length of ADT duration was
decided at the discretion of the treating urologist, and
the median duration of ADT was 4 months (range, 3–
86 months). This retrospective study was approved by the
each hospital’s local Institutional Review Board.
The implant technique and dose constraints were pre-
viously described in detail [14-16]. Early in the study
period, the preplanning method was used in the first 25
patients, and from December 2004 onward, the proced-
ure was changed to the real-time planning method. Allprocedures were conducted utilizing I-125 free seeds,
being the only approved radioisotope available for per-
manent prostate brachytherapy in Japan. The prescribed
minimum peripheral doses were 100 Gy in the preplan-
ning method era and 110 Gy in the real-time planning
method era, respectively. Post-implant dosimetry was
performed 1 month after implantation, and the minimal
dose received by 90% of the prostate (prostate D90) was
the post-implant variable analyzed.
Supplemental EBRT was delivered 4 to 8 weeks after
implantation. In general, EBRT consisted of a median
dose of 45 Gy (range, 28.8–50.4 Gy) delivered in 1.8 Gy
fractions using 6–10 MV photons delivered via a three-
dimensional conformal technique. For all patients, the
target volume consisted of the prostate gland and sem-
inal vesicles. The BED was calculated from the prostate
D90 and the EBRT dose using an α/β ratio of 2 (Gy2),
applying the formulas described previously by Stock
et al. [17]. The total BED for the combination therapy
was the sum of the BED from the implant and that from
the EBRT.
Planned follow-up was by PSA blood tests and phys-
ical examination every 3 months for the first 2 years,
every 6 months thereafter. The primary outcome meas-
ure was BFFS. Biochemical failure was determined
using the nadir +2 ng/mL definition (the Phoenix def-
inition). Patients meeting the criteria for biochemical
failure but showing a subsequent decrease to <0.5 ng/mL
without intervention were classified as having a benign
bounce, and were excluded from the analysis of failure.
Acute toxicity was considered to be symptoms developing
within the first year after implantation. Late toxicity was
defined as any symptom developing after the first year, or
symptoms that developed during the first year and per-
sisted ≥12 months. Toxicity was scored by the Common
Terminology Criteria for Adverse Events version 4.0.
Actuarial survival curves were calculated by the Kaplan-
Meier method to determine BFFS, CSS, and OS. Multi-
variate Cox regression analysis including age, PSA level,
Gleason score, positive biopsy core rates, number of high-
risk factors, neoadjuvant ADT, prostate D90, and BED
was conducted to test for predictors of BFFS. Analyses
were carried out using SPSS 20.0 (SPSS Inc., Chicago, IL,
USA). All tests were two-sided, and statistical significance
was set at p < 0.05.
Results
Clinical, treatment and dosimetric parameters for the
206 patients included in the analysis are detailed in
Table 1. The median follow-up time was 60 months
(range, 9–112 months).
Of the 206 patients, 30 developed PSA failure, yielding
an actuarial BFFS rate of 84.8% at 5 years (Figure 1).
The median time to biochemical failure was 37.2 months
Table 1 Clinical, treatment and dosimetric parameters
Median (range) Count (%)
Continuous variables
Age (years) 70 (54–86)
Initial PSA (ng/mL) 11.95 (3.7–48.0)
Positive biopsy rate (%) 33.0 (13.0–100)
Prostate D90 (Gy) 124.8 (100.0–206.5)
BED (Gy2) 213.5 (178.5–245.5)
Categorical variables
PSA level in ng/mL
<10 86 (41.7%)
10-20 39 (19.0%)















Abbreviations: PSA = prostate specific antigen; D90 = the minimal dose received
by 90% of the prostate; BED = biologically effective dose; ADT = androgen
deprivation therapy.
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20 underwent post-treatment biopsy. Five of these 20
patients had pathologically-proven local recurrence. The
patterns of clinical failure were local recurrence in 4 pa-
tients, distant metastases in 13, and both in 1. There
were 8 deaths (3.9%), of which 2 were due to prostate
cancer. The 5-year CSS for the entire cohort was 98.7%.
The 5-year OS for the entire cohort was 97.6%.
Acute grade 2 gastrointestinal (GI) and genitourinary
(GU) toxicity was experienced by 12 patients (5.8%) and
20 patients (14.5%), respectively. Late grade 2 GI and
GU toxicity was experienced by 18 patients (8.8%) and
21 patients (10.2%), respectively. None of the patients
experienced Grade ≥3 acute or late toxicity. The late
grade 2 GI toxicities primarily related to rectal bleeding
and the late grade 2 GU toxicities consisted of urinary
urgency or retention. Rectal or urethral doses were not
associated with the development of grade 2 GI or GU
toxicity on univariate analysis.On multivariate Cox regression analysis, positive biopsy
core rates and number of high-risk factors were independ-
ent predictors of BFFS by the Phoenix definition (Table 2).
The positive biopsy core rates were divided into sub-
groups: <50% (n = 130, 63.1%) and ≥50% (n = 76, 36.9%).
As shown in Figure 2, the 5-year BFFS rates for patients in
the positive biopsy core rate <50% and ≥50% groups were
89.3% and 78.2%, respectively (p = 0.03). Figure 3 shows
BFFS stratified by numbers of high-risk factors (any 1 vs.
any 2 or all 3). The 5-year BFFS rates for patients with any
single high-risk factor was 86.1%, compared with 73.6%
for those with any 2 or all 3 high-risk factors (p = 0.03).
Neoadjuvant ADT did not improve the 5-year BFFS
(87.1% vs. 82.1%, p = 0.11), according to analysis employ-
ing the log-rank test.
Discussion
Although some patients with high-risk factors may have
subclinical distant metastatic disease at diagnosis, prior
trials reported improved BFFS for patients with high-risk
prostate cancer who received higher doses of EBRT
[4-6]. This finding refutes the hypothesis that most pa-
tients with high-risk factors have subclinical distant me-
tastases at diagnosis, but rather, supports an aggressive
loco-regional treatment approach. In addition, Do et al.
reported a 5-year biochemical progression-free survival
rate of 20% for patients with Gleason scores of 8–10
who were treated with radical prostatectomy and a rate
of 30% for those given conventional doses of EBRT [18].
However, 65% of patients undergoing prostatectomy
with adjuvant EBRT were biochemically free of disease
at 5 years. This study also supports an aggressive loco-
regional treatment approach.
Brachytherapy provides a means to further escalate the
local dose and has been used in an effort to improve re-
sults in men with high-risk disease [11,12]. Stone et al.
reported a multicenter cohort study of 3,928 brachyther-
apy patients with a median follow-up of 42 months [11].
For the cohort as a whole, the respective BFFS rates for
low-, intermediate-, and high-risk patients were 84%,
77%, and 64%. However, the 1,100 men who received a
higher BED of >200 Gy via their implant, with or with-
out EBRT, had much more favorable outcomes. Among
these men, BFFS for low-, intermediate-, and high-risk
patients were 88%, 94%, and 90%, respectively. The
range seen in BED values is mostly due to inherent inac-
curacies in the implant procedure itself, with the result-
ing variation in dosimetry developing after implantation.
The EBRT dose variation stems mainly from the policy
of adjusting these doses based on the final dosimetric
outcome of the implant. As a result of these adjust-
ments, the combination of brachytherapy and EBRT re-
sulted in very high BED (median 213.5 Gy2, range
178.5–245.5 Gy2) in our study. This dose is much higher
Figure 1 Kaplan-Meier biochemical failure-free survival curve for the 206 patients in the high-risk study population.
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prescribed for intensity-modulated radiotherapy.
High-dose-rate (HDR) brachytherapy is also a technique
that allows the delivery of very high BED. Martinez et al.
performed a dose escalation investigation starting with
HDR doses of 5.5 Gy × 3 and ending with 11.5 Gy × 2 for
the HDR component of treatment [19]. The mean dose of
EBRT was 46 Gy. They found that when the BED (α/β ra-
tio of 1.2) was ≥ 268 Gy there was less biochemical failure,
better local control, and fewer cases of distant metastasis.
Kotecha et al. reported on the outcomes of 229 patients
with clinically localized prostate cancer treated with a
HDR brachytherapy boost (5.5 Gy × 3 to 7.5 Gy × 3)
followed by EBRT (most patients were treated to 50.4 Gy)
and found that a higher BED (> 190 Gy, α/β ratio of 2)Table 2 Cox regression for biochemical freedom from failure




Positive biopsy rate 0.009*




Abbreviations: CI = confidential interval; PSA = prostate specific antigen; ADT = and
of the prostate; BED = biologically effective dose.
*p < 0.05.resulted in improved BFFS and distant metastases free
survival in high-risk patients [20].
In our present study, the prognostic significance of
BFFS was investigated in high-risk prostate cancer pa-
tients and we found positive biopsy core rates and the
number of high-risk factors to be independent predictors
of BFFS. The positive biopsy core rates as determined by
transrectal ultrasound-guided biopsy have been sug-
gested as potential prognostic factors for enhancing the
standard risk stratification for prostate cancer patients
treated with EBRT [21-23]. Huang et al. analyzed 1,056
patients who were treated with modern EBRT tech-
niques and found the positive biopsy core rate to be an
independent predictor of highly relevant clinical out-
comes. The association of the positive biopsy core rate95% CI









rogen deprivation therapy; prostate D90 = the minimal dose received by 90%
Figure 2 Kaplan-Meier biochemical failure-free survival curves as a function of positive biopsy core rates. Open circles indicate the time
of last follow-up for the biochemical failure-free patients with a positive core rate <50% (n = 130). Plus symbols correspond to censored patients
with a positive core rate ≥50% (n = 76).
Figure 3 Kaplan-Meier biochemical failure-free survival curves as a function of the number of high-risk factors. Open circles indicate the
time of last follow-up for the biochemical failure-free patients with any single high-risk factor (n = 186). Plus symbols correspond to censored
patients with any 2 or all 3 high-risk factors (n = 20).
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unaffected by the use of either hormone therapy or
high-dose EBRT [22].
The relationship between the positive biopsy core rate
and BFFS has been examined in studies of patients
treated with brachytherapy [24-26]. Kestin et al. reported
on 190 men treated with a combination of EBRT and
high-dose rate brachytherapy [24]. On multivariate ana-
lysis, the positive biopsy core rate was associated with
BFFS and the development of clinical recurrence. More-
over, Merrick et al. reported on 255 men treated with
seed implantation with or without EBRT. On multivari-
ate analysis, the positive biopsy core rate and pretreat-
ment PSA level were the only significant predictors of
BFFS [25]. When low, intermediate, and high-risk pa-
tients were stratified by the positive biopsy core rate, a
non-significant trend for increased biochemical recur-
rence was observed as positive biopsy core rates rose.
The number of recurrences in their patient population
was quite low, and it is possible that their study is
underpowered to show a clinically significant effect of
positive biopsy core rates after stratification by risk
group. Rossi et al. described the 5-year estimate of the
BFFS rate as being 95% for patients with a less than 50%
positive biopsy core rate versus 63% in those with a rate
of more than 50% [26]. These reports support the results
of our present study, but the potential value of positive
biopsy core rates for predicting CSS and OS requires
longer follow-up and could not be quantified in our
present study.
Several retrospective studies have assessed the associa-
tions of the number of high-risk factors and clinical out-
comes of men given brachytherapy-based treatment
[27,28]. Wattson et al. analyzed the impact of the num-
ber of high-risk factors on prostate cancer-specific mor-
tality (PCSM) [27]. The adjusted hazard ratio for PCSM
for those with at least two high-risk factors (as com-
pared with one) was 4.8 (95% confidence interval, 2.8–
8.0; p < 0.001). When the high-risk factors were analyzed
separately, Gleason score 8–10 was most significantly as-
sociated with increased PCSM. Several studies have re-
ported similar findings for men treated with definitive
EBRT alone or EBRT plus hormone therapy, and for
men undergoing radical prostatectomy [29-31].
Our study showed that clinicians may base treatment
selection decisions on the number of high-risk factors
and positive biopsy core rates, and found that men with
more high-risk factors and a positive biopsy core rate
≥50% were likely to be selected for intensified treatments
such as trimodality therapy including brachytherapy,
EBRT and ADT. However, the results of this study
cannot be used to conclude that brachytherapy-based
trimodality therapy necessarily leads to improved rates
of control and survival as compared with alternativetreatments that do not include brachytherapy, such
as radical prostatectomy or definitive EBRT with or
without ADT.
The addition of ADT to standard dose EBRT was a
significant breakthrough for men with high-risk disease
and has resulted in major improvements in prostate
cancer-specific survival and OS [1,2]. Although ADT has
been studied in only a few trials with brachytherapy, in
one study by Merrick et al. [32], ADT improved the
10-year BFFS rate when added to the combination of
brachytherapy and EBRT versus combined therapy alone
for high-risk prostate cancer. Meanwhile, according to
the retrospective review by Lee et al. 80% of high-risk
hormone-naive patients with a high-quality implant
remained free of biochemical failure at 5 years [33]. In
our study, there were too few patients with prostate
D90 <110 Gy to obtain a dose–response curve and the
results of Lee et al. are identical to our 84.8% BFFS rate
at 5 years. These results in hormone-naive patients fur-
ther substantiate the importance of aggressive loco-
regional treatment in securing long-lasting biochemical
control in high-risk patients. A clinical randomized trial
has been conducted to investigate the efficacy of adju-
vant ADT following the combination of brachytherapy
and EBRT for high-risk prostate cancer patients in
Japan [34].
The limitations of this study are that the median
follow-up is only 60 months and it was retrospective.
Neoadjuvant ADT was administered at the discretion of
the treating urologist for reasons including prostate vol-
ume reduction or to achieve a longer waiting time until
seed implantation, therefore the duration of neoadjuvant
ADT was not controlled, though all other treatments
were uniform in most patients.Conclusions
At a median follow-up of 60 months, high-risk prostate
cancer patients who underwent combined I-125 brachy-
therapy and EBRT without adjuvant ADT have a high
probability of achieving 5-year BFFS. Positive biopsy
core rates and the number of high-risk factors signifi-
cantly impact BFFS. Additional follow-up is mandatory
to determine the durability of these results.Abbreviations
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GI: Gastrointestinal; GU: Genitourinary; HDR: High-dose-rate; PCSM: Prostate
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